Novartis Investigative Site

Hyères 83418

0 studies enrolling now · 5 studies all time

What they study most

Cancer, HER2/Neu Over-expressing Locally Advanced Breast Cancer, Heart Failure With Reduced Ejection Fraction (HF-rEF), Hormone Receptor Positive Breast Cancer, Metastatic Breast Cancer, Neoplasms, Breast, Renal Cell Carcinoma (RCC)

Studies at this site

• ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D — Completed
• Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer — Completed
• Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF) — NO_LONGER_AVAILABLE
• A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) — Completed
• Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer — Completed